RE:70% of TLT patients are CIS...I know science doesn't always work this way, but if Ruvidar works this well on the "most problematic" bladder cancer scenarios then shouldn't that mean in theory it should work just as well if not better on all bladder cancer cases? The most difficult and the most receptive. I think many here have alluded to this over the months and years. So, Theralase took the riskiest (higher odds of failure), hardest, path in treating the most resistance difficult cases... and is succeeding thus far. Right?